GlassScriptPhysician profile
James D Charasika
NPI 1043299514
$547.68
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $57.45 · 2021: $135 · 2022: $235.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155.63 | 2020-2022 | |
| Glaxosmithkline, LLC. | $136.78 | 2020-2022 | |
| Amgen INC. | $83.62 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.42 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.76 | 2021 | |
| Valeritas, INC. | $17.41 | 2019 | |
| Hologic Sales and Service, LLC | $17.31 | 2021 | |
| Gilead Sciences, INC. | $16.97 | 2019 | |
| Amarin Pharma, INC. | $14.21 | 2019 | |
| Allergan, INC. | $13.58 | 2019 | |
| Boston Scientific Corporation | $12.99 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Charasika listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.